drugset / Trial / NCT00644137
GABA (Gamma Amino Butyric Acid) Medication for Tobacco
Phase 0
Completed
24 enrolled
Yale University
National Institute on Drug Abuse (NIDA) · collabUS Department of Veterans Affairs · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The goal of this study is to examine the effects of a GABA (gamma amino butyric acid)-enhancing medication, pregabalin (300 mg/day), on smoking behavior, tobacco withdrawal and cigarette craving in smokers. We hypothesize that in smokers, pregabalin at 300 mg/day, will be more effective than placebo in decreasing smoking behavior and attenuating tobacco withdrawal and cigarette craving.
Timeline
- Start
- 2007-08
- Primary completion
- 2010-02
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pregabalin | Small molecule | 300 mg | — |